Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Abstract

Summary Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for this effect. We investigated the safety and efficacy of the combination of the IGF-1R antibody cixutumumab and the mTOR inhibitor temsirolimus in patients with chemotherapy-refractory bone and soft-tissue sarcomas according to IGF-1R expression by immunohistochemistry. Methods We undertook a multicentre, open-label, phase 2 study in 19 cancer centres in the USA. Patients aged at least 16 years with a histologically confirmed diagnosis of bone or soft-tissue sarcoma were allocated on the basis of IGF-1R expression by immunohistochemistry to one of three treatment groups: IGF-1R-positive soft-tissue sarcoma (group A), IGF-1R-positive bone sarcomas (group B), or IGF-1R-negative bone and soft-tissue sarcoma (group C). Patients received weekly treatment with cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) in 6-week cycles. A Simon optimal two-stage design was used for every arm. The primary endpoint was progression-free survival (PFS) at 12 weeks by intention-to-treat analysis in the first 54 patients assigned to every treatment arm. Although patients still remain on treatment, this trial has completed enrolment and this represents the final analysis. This study is registered with ClinicalTrials.gov, number NCT01016015. Findings Between Nov 18, 2009, and April 11, 2012, 388 patients were screened for IGF-1R expression and 54 were assigned to each arm. 17 of 54 patients in the IGF-1R-positive soft-tissue sarcoma group (31%; one-sided 95% CI lower bound 21%; two-sided 90% CI 21–43), 19 of 54 in IGF-1R-positive bone sarcoma group (35%; one-sided 95% CI lower bound 24%; two-sided 90% CI 24–47), and 21 of 54 in the IGF-1R-negative group (39%, one-sided 95% CI lower bound 28%; two-sided 90% CI 28–51) were progression free at 12 weeks. On April 6, 2011, the protocol was amended to include three additional patients in the IGF-1R-positive soft-tissue sarcoma group (total of 57 patients) and nine more in the IGF-1R-negative group (total of 63 patients). There were 2546 adverse events reported during the study, 214 (8%) of which were grade 3–4. The most common grade 3–4 toxicities in the 174 treated patients were anaemia in 16 (9%) patients, hyperglycaemia in 18 (10%), hypophosphataemia in 16 (9%), lymphopenia in 25 (14%), oral mucositis in 19 (11%), and thrombocytopenia in 19 (11%). Interpretation The combination of cixutumumab and temsirolimus shows clinical activity in patients with sarcoma and forms a basis for future trials. However, IGF-1R expression by immunohistochemistry is not predictive of clinical outcome after treatment with this combination. Funding National Cancer Institute and Cycle for Survival Fund, Memorial Sloan-Kettering Cancer Center.

Modeling Ewing sarcoma tumors in vitro with 3D scaffolds

“…Despite a wealth of preclinical information and two recent clinical trials demonstrating marked tumor regression in a subset of patients with EWS treated with combined antagonists of the IGF-1R/mTOR pathway, we noted a surprising lackluster cellular response to IGF-1R antagonists in conventional 2D monolayer culture (32,33). In seeking to elucidate biomarkers of response and mechanisms of de novo and acquired resistance, we hypothesized that this difference in preclinical and clinical response may result from inherent changes in the IGF-1R/mTOR signaling cascade when tumor cells are removed from their native microenvironment, which we sought to recapitulate using our 3D PCL scaffold while maintaining control over experimental parameters.…”

Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma

“…29 These findings suggest that the activation mechanism of the Akt/mTOR pathway is multimodal and that we should seek a combination of drugs targeting not only mTOR but also the upstream receptors and the feedback loops. 31 At this point, we cannot conclude that any of the markers we studied are useful in making the decision whether targeting this pathway is the superior strategy for each patient. In the phase 2 study of ridaforolimus, 7 pAkt, pS6, and 4E-BP1 were not identified as good predictors of a clinically beneficial response.…”

Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience

“…Also, we need more effective agents for metastatic patients. There are ongoing clinical trials investigating monoclonal antibodies, small molecule inhibitors targeting the insulin like growth factor-1 receptor (Juergens et al, 2011;Tap et al, 2012;Schwartz et al, 2013). But most of them are phase I or II trials.…”